Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Subscribe To Our Newsletter & Stay Updated
